HIV
Human Immunodeficiency Virus (HIV)
Enveloped Virus: HIV possesses an outer lipid membrane derived from the host cell, allowing fusion with host cells.
Genome: Single-stranded positive-sense RNA ().
Viral Enzymes: Contains reverse transcriptase, an enzyme essential for converting its RNA genome into DNA.
HIV Genetics
HIV has 9 gene transcripts:
gag: Group-specific antigen
pol: Polymerase (encodes reverse transcriptase, protease, and integrase)
env: Envelope proteins (including gp120 and gp41)
vif: Viral infectivity factor
vpr: Viral protein R
vpu: Viral protein U
nef: Negative-regulation factor
tat: Transactivator (upregulates transcription)
rev: Regulator of viral expression (allows export of unspliced/partially spliced transcripts)
HIV Structure and Life Cycle
Attachment:
Uses gp120 to bind to CD4 on T cells and CCR5/CXCR4 co-receptors.
gp41 facilitates fusion of the virus with the host's cell membrane.
Cell Tropism:
Different strains target different cells:
T-cell tropic strains use CXCR4.
Macrophage-tropic strains use CCR5.
HIV Replication Cycle:
Virion binds to CD4 and co-receptor.
Viral envelope fuses with the cell membrane, releasing viral RNA into the cytoplasm.
Reverse transcriptase transcribes RNA into double-stranded cDNA.
cDNA integrates into host DNA.
Cellular machinery transcribes viral DNA, producing RNA transcripts and proteins (Gag, Pol, Env).
Assembly and budding of new virions from the cell surface.
Disease Progression
HIV Infection Stages:
Primary Infection: Symptoms appear (acute HIV syndrome); virus disseminates widely.
Clinical latency: Virus levels stabilize; CD4+ T cell counts begin to drop over time.
AIDS: Progressive immune dysfunction leads to opportunistic infections.
CD4+ T Lymphocyte Count:
Typical count in healthy individuals: 500-1200 cells/mm³.
Counts below 200 cells/mm³ indicate AIDS and higher risk of opportunistic infections.
Opportunistic Infections and Malignancies
AIDS Complications:
Vulnerable to infections by certain bacteria, viruses, fungi, and parasites such as Tuberculosis and Pneumocystis carinii.
Increased risk of certain malignancies including Kaposi's sarcoma and non-Hodgkin's lymphoma.
Transmission and Prevention
Routes of Transmission:
Sexual contact, breast milk, blood-contaminated needles, organ transplants, and transfusions.
Most common source: heterosexual intercourse (85% of cases).
Preventive Measures:
Use of condoms, sterile needles, and regular testing for high-risk communities.
HIV Treatment: HAART
Highly Active Antiretroviral Therapy (HAART):
Combines multiple antiretroviral drugs that target different stages of the viral life cycle (e.g., reverse transcriptase inhibitors, protease inhibitors, etc.).
HAART does not eliminate HIV but reduces viral load and minimizes transmission risk.
Long-term therapy aims to increase the number of uninfected CD4+ cells.
Drug Resistance:
Over 75% of HIV infections can develop resistance to some medications, necessitating careful management of therapy.
Current Statistics and Global Impact
Global HIV/AIDS Statistics (2020):
Approximately 37.7 million people living with HIV.
680,000 AIDS-related deaths.
New infections: 1.5 million annually.
Future Directions and Goals
U.S. Goals:
Reduce new HIV infections by 75% by 2025, aiming for 90% reduction by 2030.
Emphasis on quick diagnosis, effective treatment, and preventive measures like PrEP to halt transmission.
Enveloped Virus: HIV possesses an outer lipid membrane derived from the host cell, facilitating the fusion of the virus with the host's cells. This membrane aids in evading the host's immune system, allowing HIV to persist and replicate effectively within the host.
Genome: The genome of HIV is composed of single-stranded positive-sense RNA (), which serves as the template for the synthesis of viral proteins and replication. The RNA genome is encased within a protein shell known as the capsid, which is crucial for the virus's structural integrity and stability.
Viral Enzymes: HIV contains essential viral enzymes, including reverse transcriptase, responsible for converting its RNA genome into DNA, allowing the viral genetic material to integrate into the host's genome, and protease, which cleaves viral proteins for the maturation of new virions. Additionally, integrase enables the incorporation of viral DNA into the host’s DNA, marking a critical step in the virus's life cycle.
HIV Genetics
HIV has 9 distinct gene transcripts, each playing a pivotal role in the viral life cycle and pathogenesis:
gag: Group-specific antigen, crucial for forming the viral capsid and matrix.
pol: Polymerase, encodes for enzymes including reverse transcriptase, protease, and integrase vital for viral replication and maturation.
env: Envelope proteins, which include gp120 and gp41, facilitate binding and fusion with host cells.
vif: Viral infectivity factor, enhances viral replication by combating host cell defenses.
vpr: Viral protein R, plays roles in viral DNA integration and modulation of host cell functions.
vpu: Viral protein U, aids in the enhancement of viral release from infected cells and degradation of CD4 molecules.
nef: Negative-regulation factor, downregulates CD4 receptor and MHC class I molecules, reducing immune recognition.
tat: Transactivator, upregulates transcription of viral genes, boosting the efficiency of the viral life cycle.
rev: Regulator of viral expression, facilitates the export of unspliced and partially spliced transcripts from the nucleus to the cytoplasm, allowing for protein synthesis.
HIV Structure and Life Cycle
Attachment:
HIV utilizes the surface protein gp120 to bind to the CD4 receptor present on T cells, along with co-receptors CCR5 or CXCR4, depending on the viral strain. This binding is a critical first step in facilitating the viral entry into the host cell.
The fusion protein gp41 aids in the fusion of the viral envelope with the host's cell membrane, allowing the viral contents to enter the host cell.
Cell Tropism:
Different strains of HIV exhibit specificity in targeting host cells:
T-cell tropic strains preferentially utilize CXCR4 co-receptors, primarily affecting activated T lymphocytes.
Macrophage-tropic strains employ CCR5 co-receptors, enabling the virus to infect macrophages and dendritic cells involved in immune response.
HIV Replication Cycle:
Virion binds to CD4 and co-receptor.
Viral envelope fuses with the cell membrane, releasing viral RNA genomes and associated enzymes (reverse transcriptase, integrase) into the cytoplasm.
Reverse transcriptase converts the viral RNA into double-stranded complementary DNA (cDNA).
cDNA is transported into the nucleus, where viral integrase facilitates its integration into the host's DNA.
The integrated viral DNA (provirus) is transcribed by the host's machinery into mRNA, producing RNA transcripts and viral proteins (Gag, Pol, Env).
Newly synthesized viral proteins and RNA genomes are assembled into new virions.
The new virions bud from the host cell membrane, acquiring an envelope and ready to infect additional cells.
Disease Progression
HIV Infection Stages:
Primary Infection: Symptoms may appear within 2 to 4 weeks (acute HIV syndrome), with the virus disseminating widely in the body and the immune system responding.
Clinical Latency: The viral replication stabilizes, often leading to asymptomatic periods lasting years, but the virus continues to replicate at low levels, and CD4+ T cell counts begin to decline over time.
AIDS: Progressive immune dysfunction emerges, making patients susceptible to opportunistic infections and certain malignancies due to a critically low CD4+ T lymphocyte count.
CD4+ T Lymphocyte Count:
Typical count in healthy individuals ranges from 500 to 1200 cells/mm³.
Counts dropping below 200 cells/mm³ indicate progression to AIDS and a significantly increased risk of opportunistic infections.
Opportunistic Infections and Malignancies
AIDS Complications:
Individuals with AIDS are particularly vulnerable to infections caused by pathogens that rarely cause disease in immunocompetent individuals, including
Bacterial infections (e.g., Tuberculosis)
Viral infections (e.g., Cytomegalovirus)
Fungal infections (e.g., Pneumocystis carinii pneumonia)
Parasitic infections (e.g., Toxoplasmosis)
Additionally, there is an increased risk of specific malignancies such as Kaposi's sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer due to impaired immune surveillance.
Transmission and Prevention
Routes of Transmission:
HIV can be transmitted through several routes, including:
Unprotected sexual contact (most prevalent route, particularly heterosexual intercourse)
Breast milk from an infected mother
Sharing of blood-contaminated needles or syringes
Receiving infected organ transplants or blood transfusions
Preventive Measures:
Effective strategies to prevent HIV transmission include:
Consistent use of condoms during sexual intercourse.
Utilization of sterile needles and syringes in healthcare and among drug users.
Regular HIV testing, particularly in high-risk populations, to facilitate early detection and treatment, reducing the risk of transmission to others.
HIV Treatment: HAART
Highly Active Antiretroviral Therapy (HAART):
HAART involves a combination of multiple antiretroviral drugs that target various stages of the viral life cycle (e.g., reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors). While it does not eliminate HIV from the body, HAART significantly reduces viral load, improves immune function, and minimizes the risk of transmission.
Long-term therapy aims to restore and maintain a sufficient number of uninfected CD4+ cells, yet the emergence of drug resistance remains a challenge.
Approximately over 75% of HIV infections can develop resistance to some medications, underscoring the necessity for vigilant management of therapy and potential adjustments in treatment regimens.
Current Statistics and Global Impact
Global HIV/AIDS Statistics (2020):
An estimated 37.7 million individuals are living with HIV worldwide. In the same year, approximately 680,000 deaths were attributed to AIDS-related complications, and 1.5 million new infections were reported annually, showcasing the ongoing public health challenge presented by the HIV pandemic.
Future Directions and Goals
U.S. Goals:
By 2025, to reduce new HIV infections by 75%, with an ambitious aim of a 90% reduction by 2030. Efforts focus on:
Quick diagnosis and initiating timely treatment.
Implementing effective prevention methods, including pre-exposure prophylaxis (PrEP), to curb transmission rates in at-risk populations, ensuring continued public health awareness and education on HIV.
Enveloped Virus: HIV possesses an outer lipid membrane derived from the host cell, facilitating the fusion of the virus with the host's cells. This membrane aids in evading the host's immune system, allowing HIV to persist and replicate effectively within the host.
Genome: The genome of HIV is composed of single-stranded positive-sense RNA (), which serves as the template for the synthesis of viral proteins and replication. The RNA genome is encased within a protein shell known as the capsid, which is crucial for the virus's structural integrity and stability.
Viral Enzymes: HIV contains essential viral enzymes, including reverse transcriptase, responsible for converting its RNA genome into DNA, allowing the viral genetic material to integrate into the host's genome, and protease, which cleaves viral proteins for the maturation of new virions. Additionally, integrase enables the incorporation of viral DNA into the host’s DNA, marking a critical step in the virus's life cycle.
HIV Genetics
HIV has 9 distinct gene transcripts, each playing a pivotal role in the viral life cycle and pathogenesis:
gag: Group-specific antigen, crucial for forming the viral capsid and matrix.
pol: Polymerase, encodes for enzymes including reverse transcriptase, protease, and integrase vital for viral replication and maturation.
env: Envelope proteins, which include gp120 and gp41, facilitate binding and fusion with host cells.
vif: Viral infectivity factor, enhances viral replication by combating host cell defenses.
vpr: Viral protein R, plays roles in viral DNA integration and modulation of host cell functions.
vpu: Viral protein U, aids in the enhancement of viral release from infected cells and degradation of CD4 molecules.
nef: Negative-regulation factor, downregulates CD4 receptor and MHC class I molecules, reducing immune recognition.
tat: Transactivator, upregulates transcription of viral genes, boosting the efficiency of the viral life cycle.
rev: Regulator of viral expression, facilitates the export of unspliced and partially spliced transcripts from the nucleus to the cytoplasm, allowing for protein synthesis.
HIV Structure and Life Cycle
Attachment:
HIV utilizes the surface protein gp120 to bind to the CD4 receptor present on T cells, along with co-receptors CCR5 or CXCR4, depending on the viral strain. This binding is a critical first step in facilitating the viral entry into the host cell.
The fusion protein gp41 aids in the fusion of the viral envelope with the host's cell membrane, allowing the viral contents to enter the host cell.
Cell Tropism:
Different strains of HIV exhibit specificity in targeting host cells:
T-cell tropic strains preferentially utilize CXCR4 co-receptors, primarily affecting activated T lymphocytes.
Macrophage-tropic strains employ CCR5 co-receptors, enabling the virus to infect macrophages and dendritic cells involved in immune response.
HIV Replication Cycle:
Virion binds to CD4 and co-receptor.
Viral envelope fuses with the cell membrane, releasing viral RNA genomes and associated enzymes (reverse transcriptase, integrase) into the cytoplasm.
Reverse transcriptase converts the viral RNA into double-stranded complementary DNA (cDNA).
cDNA is transported into the nucleus, where viral integrase facilitates its integration into the host's DNA.
The integrated viral DNA (provirus) is transcribed by the host's machinery into mRNA, producing RNA transcripts and viral proteins (Gag, Pol, Env).
Newly synthesized viral proteins and RNA genomes are assembled into new virions.
The new virions bud from the host cell membrane, acquiring an envelope and ready to infect additional cells.
Disease Progression
HIV Infection Stages:
Primary Infection: Symptoms may appear within 2 to 4 weeks (acute HIV syndrome), with the virus disseminating widely in the body and the immune system responding.
Clinical Latency: The viral replication stabilizes, often leading to asymptomatic periods lasting years, but the virus continues to replicate at low levels, and CD4+ T cell counts begin to decline over time.
AIDS: Progressive immune dysfunction emerges, making patients susceptible to opportunistic infections and certain malignancies due to a critically low CD4+ T lymphocyte count.
CD4+ T Lymphocyte Count:
Typical count in healthy individuals ranges from 500 to 1200 cells/mm³.
Counts dropping below 200 cells/mm³ indicate progression to AIDS and a significantly increased risk of opportunistic infections.
Opportunistic Infections and Malignancies
AIDS Complications:
Individuals with AIDS are particularly vulnerable to infections caused by pathogens that rarely cause disease in immunocompetent individuals, including
Bacterial infections (e.g., Tuberculosis)
Viral infections (e.g., Cytomegalovirus)
Fungal infections (e.g., Pneumocystis carinii pneumonia)
Parasitic infections (e.g., Toxoplasmosis)
Additionally, there is an increased risk of specific malignancies such as Kaposi's sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer due to impaired immune surveillance.
Transmission and Prevention
Routes of Transmission:
HIV can be transmitted through several routes, including:
Unprotected sexual contact (most prevalent route, particularly heterosexual intercourse)
Breast milk from an infected mother
Sharing of blood-contaminated needles or syringes
Receiving infected organ transplants or blood transfusions
Preventive Measures:
Effective strategies to prevent HIV transmission include:
Consistent use of condoms during sexual intercourse.
Utilization of sterile needles and syringes in healthcare and among drug users.
Regular HIV testing, particularly in high-risk populations, to facilitate early detection and treatment, reducing the risk of transmission to others.
HIV Treatment: HAART
Highly Active Antiretroviral Therapy (HAART):
HAART involves a combination of multiple antiretroviral drugs that target various stages of the viral life cycle (e.g., reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors). While it does not eliminate HIV from the body, HAART significantly reduces viral load, improves immune function, and minimizes the risk of transmission.
Long-term therapy aims to restore and maintain a sufficient number of uninfected CD4+ cells, yet the emergence of drug resistance remains a challenge.
Approximately over 75% of HIV infections can develop resistance to some medications, underscoring the necessity for vigilant management of therapy and potential adjustments in treatment regimens.
Current Statistics and Global Impact
Global HIV/AIDS Statistics (2020):
An estimated 37.7 million individuals are living with HIV worldwide. In the same year, approximately 680,000 deaths were attributed to AIDS-related complications, and 1.5 million new infections were reported annually, showcasing the ongoing public health challenge presented by the HIV pandemic.
Future Directions and Goals
U.S. Goals:
By 2025, to reduce new HIV infections by 75%, with an ambitious aim of a 90% reduction by 2030. Efforts focus on:
Quick diagnosis and initiating timely treatment.
Implementing effective prevention methods, including pre-exposure prophylaxis (PrEP), to curb transmission rates in at-risk populations, ensuring continued public health awareness and education on HIV.